Klebsiella Susceptibility to Cefotaxime
Klebsiella species are generally susceptible to cefotaxime when they do not produce extended-spectrum β-lactamases (ESBLs) or other resistance mechanisms, but ESBL-producing strains—which are increasingly common—are resistant and should not be treated with cefotaxime despite in vitro susceptibility results. 1
Baseline Susceptibility
Wild-type Klebsiella pneumoniae and K. oxytoca are inherently susceptible to cefotaxime. The FDA label explicitly lists Klebsiella spp. (including K. pneumoniae) among organisms against which cefotaxime demonstrates activity both in vitro and in clinical infections 1. Historical data from Pakistan showed 66.6% susceptibility of Klebsiella isolates to cefotaxime 2, though this varies significantly by region and time period.
The ESBL Problem: A Critical Caveat
The major clinical pitfall is that ESBL-producing Klebsiella strains render cefotaxime ineffective, even when laboratory testing suggests susceptibility. This is the single most important consideration when evaluating cefotaxime use:
ESBL prevalence is rising globally. Studies show ESBL production in 18.4% of K. pneumoniae urinary isolates in Nepal 3 and increasing rates in Japan from 4.5% in 2005 to 23% in 2009 4
Standard breakpoints fail to identify many ESBL producers. The 2010 CLSI consensus statement explicitly warns that susceptible breakpoints for third-generation cephalosporins (including cefotaxime ≤1 μg/mL) failed to identify many ESBL-producing K. pneumoniae strains 5
Clinical efficacy is uncertain even with "susceptible" MICs. Guidelines state that indications for using third-generation cephalosporins to treat ESBL-producing K. pneumoniae with lower MICs remain unclear 5
Resistance Mechanisms Beyond ESBLs
Additional resistance patterns further complicate susceptibility:
Most ESBL-producing and carbapenemase-producing isolates are resistant to cefotaxime 1
Plasmid-mediated AmpC β-lactamases also confer resistance. Cefotaxime with MIC >1 μg/mL had 98.3% sensitivity and 99.7% specificity for detecting ESBL or plasmid-mediated AmpC 4
blaSHV-1 amplification on epidemic plasmids can cause resistance to multiple β-lactams while maintaining cefotaxime susceptibility 6
Clinical Recommendations
When considering cefotaxime for Klebsiella infections:
Always perform ESBL screening if treating with cefotaxime, even if initial susceptibility testing shows sensitivity 5
If ESBL-positive, use a carbapenem instead (imipenem, meropenem, or ertapenem), which remain the most active agents 5, 7
For confirmed non-ESBL, cefotaxime-susceptible strains, cefotaxime is appropriate, though ceftriaxone is more commonly used for bacteremia 8
In critically ill patients or high-risk settings (prior multidrug-resistant bacteria, previous oxyimino-cephalosporin or fluoroquinolone use, high SOFA scores), empiric carbapenem therapy is safer than cefotaxime given the high mortality associated with inappropriate empirical therapy for ESBL strains (21% vs 5% for susceptible strains) 4
Geographic Considerations
Susceptibility patterns vary dramatically by region. Russian data showed only 16.9% of nosocomial Klebsiella susceptible to cefotaxime 7, while Chilean isolates showed better activity 9. Always consult local antibiograms before empiric cefotaxime use, as the FDA label emphasizes that susceptibility varies geographically and changes over time 1.